Skip to main content

Table 2 Baseline characteristics of studies included in the meta-analysis

From: Internal jugular vein versus subclavian vein as the percutaneous insertion site for totally implantable venous access devices: a meta-analysis of comparative studies

Study

Country

Design

Participants

Use of heparin flushing

Antibiotic prophylaxis

Ultrasound guidance

Matching criteriaa

Follow-upb, IJV/SCV

Age, yr (median/mean)

Range

TIVAD

IJV

SCV

Araujoc [15], 2008

Portugal

PC

55.5 (median)

15–83

Mini-sitimplant

512

551

Y

N

N

1,2,3,4,5

244/363d (median)

Biffi [16], 2009

Italy

RCT

51.9 (mean)

18–75

Bard Port

117

123

Y

NR

Only for SCV

1,2,4,6,7,8

384/360d (median)

Plumhans [31], 2011

Germany

PC

56 (mean)

18–85

Bard Port

44

94

Y

NR

Only for IJV

7,8

6 mo (mean)

AribaÅŸ [38], 2012

Turkey

RC

53.8 (mean)

16–84

Polysite

248

99

Y

NR

Y

1,2,4,7,8

219.5d (mean)

Ribeiro [39], 2012

Brazil

RCT

< 18 yr

NR

NR

34

43

Y

Y

N

1,2,4,6,7,8

14.8/12.6 mo (mean)

Vetter [21], 2013

Germany

RC

53 (mean)

2–84

INTRAPORT

71

32

Y

Y

N

1,2

451d (mean)

Liud [40], 2014

China

RC

45.4 (mean)

8–86

Bardport

222

398

Y

NR

N

1,2,3,4

1079.3/995.2d (mean)

Miao [41], 2014

China

RCT

58.1 (mean)

25–81

NR

107

107

Y

Y

Only for IJV

1,2,3,4,8

215/209d (mean)

Nagasawae [17], 2014

Japan

RC

64 (median)

25–85

BARD X-port isp

136

97

NR

NR

Only for IJV

3

566/402d (mean)

Ozbudak [42], 2014

Turkey

RC

56.38 (mean)

14–83

FB Medical/Districlass medical SA

178

224

Y

N

Y for some patients

3,8

507d (median)

Wu [18], 2014

Taiwan

RC

57.7 (mean)

0.5–94

Arrow/Bard/ Tyco

63

234

Y

NR

N

NA

4.5 yr (mean)

Jung [23], 2015

Korea

RC

59 (median)

1–82

Bard Port

92

79

NR

NR

N

1,2,4,7

278d (median)

  1. Abbreviations: d days, mo months, N No, NR data not reported, PC prospective cohort study, RC retrospective cohort study, US ultrasound guidance, Y Yes, yr years
  2. afor matching criteria: 1 = age; 2 = gender; 3 = completion of the TIVAD insertion; 4 = site of primary malignancy; 5 = time of surgery; 6 = side; 7 = TIVAD outer diameter; 8 = coagulation parameters; 9 = body mass index
  3. bMean or median dwell time
  4. cOnly 512 and 551 patients were included in the analysis for group IJV and SCV respectively
  5. dOne catheter fracture due to iatrogenic injury was not included in the analysis
  6. eOne case of pin hole leakage in the IJV arm was included in the major mechanical complications